Boston Scientific Q1 2025 10-Q Filed

Ticker: BSX · Form: 10-Q · Filed: May 1, 2025 · CIK: 885725

Boston Scientific CORP 10-Q Filing Summary
FieldDetail
CompanyBoston Scientific CORP (BSX)
Form Type10-Q
Filed DateMay 1, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, medical-devices

TL;DR

**BSX Q1 2025 10-Q is in! Financials and ops updates are live.**

AI Summary

Boston Scientific Corporation filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial figures and strategic developments are presented, reflecting the company's ongoing business activities and market position in the medical device sector.

Why It Matters

This filing provides investors and analysts with the latest financial and operational data for Boston Scientific, crucial for understanding the company's performance and future outlook in the competitive medical technology market.

Risk Assessment

Risk Level: medium — The company operates in the highly regulated and competitive medical device industry, facing risks related to product development, market adoption, and regulatory approvals.

Key Numbers

Key Players & Entities

FAQ

What is the reporting period for this 10-Q filing?

The reporting period is for the quarter ended March 31, 2025.

When was this 10-Q filed with the SEC?

This 10-Q was filed on May 1, 2025.

What is Boston Scientific Corporation's Standard Industrial Classification code?

Boston Scientific Corporation's SIC code is 3841, for SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.

What is the company's fiscal year end?

The company's fiscal year ends on December 31.

What is the company's primary business address?

The company's business address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA 01752-1234.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 1, 2025 regarding BOSTON SCIENTIFIC CORP (BSX).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing